Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb optimal dose-finding study of P1101 in Japanese patients with polycythemia vera
jRCT2031230267Phase 3Active, not recruiting
- Sponsor
- PharmaEssentia
- Start
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ropeginterferon alfa-2b in polycythemia vera (PV), sponsored by PharmaEssentia. Primary endpoint: Phlebotomy-free complete hematologic response rate at Week 24. Started Jul 2023; status: active, not recruiting.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on jRCT2031230267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230267.